Drugs / U-500 Insulin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02148250 | Jul 2015 → Dec 2017 | type 2 diabetes mellitus | University of Minnesota | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00606034 | Dec 2007 → Jul 2009 | type 2 diabetes mellitus | Mountain Diabetes and Endocrine Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-06-25 | Eli Lilly and Company | Results First-ever Study of Lilly's Humulin® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes lilly.com ↗
At the study's primary endpoint of 26 weeks, Humulin R U-500 delivered in the investigational pump and through MDI led to A1C reductions from baseline in people with type 2 diabetes (-1.27 percent, -0.85 percent, respectively). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-06-25 | Eli Lilly and Company | First-ever Study of Lilly's Humulin® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes lilly.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | U-500 insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02148250 ↗ |
| Known as | U-500 regular insulin | “The hypothesis that using a concentrated form of insulin called U-500 Regular insulin and delivering it by infusion via insulin pump will lower the volume of insulin required...” NCT00606034 ↗1“The study will the start when by giving you a dose of either 100 or 200 units of U-500 regular insulin subcutaneously in random order (like a flip of a coin).” NCT02148250 ↗ |
| Route | Subcutaneous | “U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod” NCT00606034 ↗ |